Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | July 2013 |
End Date: | September 2016 |
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to compare the progression-free survival of patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with
VTX-2337 + cisplatin or carboplatin + 5-FU + cetuximab versus patients treated with
cisplatin or carboplatin + 5-FU + cetuximab alone (standard-of-care; SOC). Safety and
overall survival will also be evaluated.
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with
VTX-2337 + cisplatin or carboplatin + 5-FU + cetuximab versus patients treated with
cisplatin or carboplatin + 5-FU + cetuximab alone (standard-of-care; SOC). Safety and
overall survival will also be evaluated.
This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the
safety and efficacy of VTX 2337 in combination with cisplatin or carboplatin, 5-FU and
cetuximab in prolonging the progression-free survival in subjects with recurrent or
metastatic squamous cell carcinoma of the head and neck.
OBJECTIVES:
Primary Objective:
To compare the efficacy of VTX 2337 plus SOC to SOC alone in prolonging the PFS of patients
with recurrent or metastatic SCCHN.
Secondary Objectives:
To compare the following between the two treatment groups:
- Safety of VTX 2337 by adverse events, including clinically significant changes in
physical examination, peripheral blood hematology, serum chemistry, urinalysis, and
ECG.
- Efficacy of VTX 2337 plus SOC in prolonging the OS of patients with recurrent or
metastatic SCCHN.
- Efficacy of VTX-2337 plus SOC on ORR, DOBR, DCR, and DDC by irRECIST and evaluation by
independent radiology review.
Exploratory Objectives:
- To compare genetic polymorphisms that may impact the response of patients to a TLR8
agonist or to cetuximab between the two treatment groups.
- To compare immune biomarker response to VTX 2337 plus SOC as measured by a multiplexed
panel of cytokines, chemokines, and inflammatory markers between the two treatment
groups.
- To compare the effect of immune cell subsets within the tumor on response to VTX-2337
and/or clinical outcome, as measured by immunohistochemistry in primary tumor tissue
between the two treatment groups.
- To assess the PK of VTX-2337.
OUTLINE:
Subjects will be screened for eligibility (within 14 days) and qualified subjects will be
randomized 1:1 to 1 of 2 treatment groups: SOC + VTX 2337 or SOC + placebo.
Tumor assessments will be by CT or MRI starting at Week 12 (± 3 days), then at Week 18 (± 3
days) and every 8 weeks (± 7 days) thereafter. Response will be evaluated by immune-related
RECIST criteria (irRECIST) and confirmed by an independent radiologist.
Upon independent confirmation of disease progression, active participation in the study is
complete and subjects will undergo the End of Treatment evaluations.
Subjects will be followed for survival until ~12 months after the last subject is
randomized.
safety and efficacy of VTX 2337 in combination with cisplatin or carboplatin, 5-FU and
cetuximab in prolonging the progression-free survival in subjects with recurrent or
metastatic squamous cell carcinoma of the head and neck.
OBJECTIVES:
Primary Objective:
To compare the efficacy of VTX 2337 plus SOC to SOC alone in prolonging the PFS of patients
with recurrent or metastatic SCCHN.
Secondary Objectives:
To compare the following between the two treatment groups:
- Safety of VTX 2337 by adverse events, including clinically significant changes in
physical examination, peripheral blood hematology, serum chemistry, urinalysis, and
ECG.
- Efficacy of VTX 2337 plus SOC in prolonging the OS of patients with recurrent or
metastatic SCCHN.
- Efficacy of VTX-2337 plus SOC on ORR, DOBR, DCR, and DDC by irRECIST and evaluation by
independent radiology review.
Exploratory Objectives:
- To compare genetic polymorphisms that may impact the response of patients to a TLR8
agonist or to cetuximab between the two treatment groups.
- To compare immune biomarker response to VTX 2337 plus SOC as measured by a multiplexed
panel of cytokines, chemokines, and inflammatory markers between the two treatment
groups.
- To compare the effect of immune cell subsets within the tumor on response to VTX-2337
and/or clinical outcome, as measured by immunohistochemistry in primary tumor tissue
between the two treatment groups.
- To assess the PK of VTX-2337.
OUTLINE:
Subjects will be screened for eligibility (within 14 days) and qualified subjects will be
randomized 1:1 to 1 of 2 treatment groups: SOC + VTX 2337 or SOC + placebo.
Tumor assessments will be by CT or MRI starting at Week 12 (± 3 days), then at Week 18 (± 3
days) and every 8 weeks (± 7 days) thereafter. Response will be evaluated by immune-related
RECIST criteria (irRECIST) and confirmed by an independent radiologist.
Upon independent confirmation of disease progression, active participation in the study is
complete and subjects will undergo the End of Treatment evaluations.
Subjects will be followed for survival until ~12 months after the last subject is
randomized.
Inclusion Criteria:
- Ability and willingness to provide written informed consent
- Histologically or cytologically confirmed squamous cell carcinoma of the head and
neck
- Locoregionally recurrent or metastatic disease that has not previously been treated
with systemic therapy of recurrent or metastatic disease
- At least one measurable lesion on screening CT or MRI
- 18 years of age or older
- ECOG performance status of 0 or 1
- Acceptable bone marrow, renal, and hepatic function based upon screening lab tests
- Willingness to use medically acceptable contraception
- For females with reproductive potential: a negative serum pregnancy test
Exclusion Criteria:
- Disease which is amenable to curative local therapy
- Nasopharyngeal, salivary gland, lip or sinonasal carcinoma
- Surgery or irradiation ≤ 4 weeks prior to randomization
- Prior systemic anti-cancer therapy, unless administered for localized SCCHN and
completed at least 6 months prior to disease recurrence
- Treatment with an investigational agent ≤ 30 days prior to randomization
- Treatment with corticosteroids within 2 weeks
- A requirement for chronic systemic immunosuppressive therapy for any reason
- Prior serious infusion reaction to cetuximab
- Treatment with an immunotherapy within 30 days
- Known brain metastases, unless stable for at least 28 days
- Active autoimmune disease currently requiring therapy
- Known infection with HIV
- Significant cardiac disease within 6 months
- Pregnant or breast-feeding females
- History of another primary malignancy, with the exception of (i) curatively resected
non-melanoma skin cancer, (ii) curatively treated in situ cervical cancer, or (iii)
other malignancy curatively treated with no evidence of disease and no anticancer
therapy administered for 3 years prior to randomization, with the exception of
adjuvant hormonal therapy for breast cancer
- Other conditions or circumstances that could interfere with the study
We found this trial at
53
sites
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
Click here to add this to my saved trials
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Univ of Texas, Southwestern Med Ctr of Dallas The story of UT Southwestern Medical Center...
Click here to add this to my saved trials
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
Bethesda, Maryland 20889
(301) 295-4000
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
303 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
Click here to add this to my saved trials
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
University Hospitals of Cleveland The history of University Hospitals Case Medical Center is linked to...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Tripler Army Medical Center The attack of Pearl Harbor led to the construction of Tripler...
Click here to add this to my saved trials
Click here to add this to my saved trials
Monter Cancer Center The Monter Cancer Center is a unique facility dedicated to providing state-of-the-art...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
The West Clinic, PC Hello and welcome to our office. Although it is our pleasure...
Click here to add this to my saved trials
Click here to add this to my saved trials
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
5150 Centre Ave
Pittsburgh, Pennsylvania 15232
Pittsburgh, Pennsylvania 15232
(412) 647-2811
University of Pittsburgh Cancer Institute Founded in 1985, the University of Pittsburgh Cancer Institute (UPCI)...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Barnes Jewish Hospital Barnes-Jewish Hospital at Washington University Medical Center is the largest hospital in...
Click here to add this to my saved trials
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
Click here to add this to my saved trials
Madigan Army Medical Center Located on Joint Base Lewis-McChord, Madigan Army Medical Center comprises a...
Click here to add this to my saved trials
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials